Navigation Links
Breast Cancer Patients Take DNA Test to Determine Best Treatment
Date:10/30/2008

SEATTLE, Oct. 30 /PRNewswire/ -- Nearly one third of breast cancer patients prescribed tamoxifen currently fail treatment. According to the National Foundation for Cancer Research (NFCR), this failure rate can be reduced to less than ten percent, saving 20,000 lives each year, by having patients take a simple DNA test and properly managing their medications.

Recent research shows that tamoxifen has to be activated into endoxifen by the liver enzyme CYP2D6. Endoxifen is the medicine that prevents the recurrence of estrogen receptive positive cancers.

About ten percent of breast cancer patients prescribed tamoxifen are missing CYP2D6 because of their DNA, and will fail tamoxifen treatment. "Patients want to know that tamoxifen will definitely benefit them, before committing to take it for five years. DNA testing offers them the reassurance that their tamoxifen is effective," stated Dr. Michael Benjamin, oncologist and editor of the medical news website, InteractMD.com

Breast cancer patients can also fail tamoxifen treatment by unknowingly taking other prescription drugs, herbals preparations, or over-the-counter medicines that interfere with CYP2D6 activity. Many classes of drugs, including anti-depressants, prevent CYP2D6 from converting tamoxifen into endoxifen. That's why Genelex includes password-protected access to their GeneMedRx software program with each test. Patients enter all of the drugs they take and produce a report to learn if any of the drugs they take might be defeating their endoxifen treatment.

"Patients and physicians need to be aware that DNA testing for tamoxifen effectiveness is available now. There is typically a 10-year gap between research and application in the clinical setting. We need to shorten that time when people's lives are at stake -- as they are with tamoxifen," stated Genelex founder and CEO Howard Coleman.

For more information about the CYP2D6 DNA test, visit Genelex at http://www.HealthandDNA.com, or call (800) 532-3080. Genelex donates a portion of all tests purchased to the National Foundation for Cancer Research.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Howard Coleman

http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=44528


'/>"/>
SOURCE Genelex Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
4. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
5. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
6. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
7. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
8. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer
11. Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 2016 , ... Kara Dwyer Dodge grew up hearing stories of the sea monster her father ... found a sea turtle entangled in the lines of one of his lobster pots. He ... because no one could remember ever seeing one so large so close to shore. After ...
(Date:12/6/2016)... Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today reported its ... ended September 30, 2016. ... , SQI is a ... develops and commercializes proprietary technologies and products for advanced multiplexed diagnostics. ... $1.4 million more than tripling prior years revenue. ...
(Date:12/6/2016)... ... December 06, 2016 , ... The ... asking the Federal Drug Administration (FDA) to consider OA as a serious disease. ... concerned about the growing population of OA patients, many of whom may experience ...
(Date:12/6/2016)... and Albany, NY (PRWEB) , ... December 06, ... ... control system integrator of custom industrial automation and IT solutions, today announced the ... Superior Controls has reliably delivered professionally executed automation and control systems integration services ...
Breaking Biology Technology:
(Date:11/21/2016)... 21, 2016   Neurotechnology , a provider ... today announced that the MegaMatcher On Card fingerprint ... for the NIST Minutiae Interoperability Exchange (MINEX) ... mandatory steps of the evaluation protocol. ... test of fingerprint templates used to establish compliance ...
(Date:11/16/2016)... Calif. , Nov. 16, 2016 ... user experience and security for consumer electronics, and ... the financial and retail industry, today announced a ... and convenient way to authenticate users of mobile ... Sensory,s TrulySecure™ software which requires no ...
(Date:11/14/2016)... 14, 2016  Based on its recent ... & Sullivan recognizes FST Biometrics with the ... Visionary Innovation Leadership. FST Biometrics emerged as ... market by pioneering In Motion Identification (IMID) ... seamless, and non-invasive verification. This patented solution ...
Breaking Biology News(10 mins):